Navigation Links
Cardiovascular fitness not affected by cancer treatment
Date:5/28/2009

Washington, DC The cardiovascular fitness level of cancer survivors is not affected by many standard cancer therapies, say researchers from Georgetown University Medical Cancer. That is the finding of a new observational study to be presented today at the American College of Sports Medicine in Seattle.

"We know physical activity is a critical component of cancer survivorship, both during and after cancer treatment," says Jennifer LeMoine, PhD, a post-doctoral research fellow with training in exercise physiology at GUMC's Lombardi Comprehensive Cancer Center. "In order to prescribe an exercise program, it's critical that we understand our patient's fitness level and whether or not treatment has had an impact on their cardiovascular health."

For the study, the researchers conducted a chart review of 49 women who attended a physician-directed fitness clinic for cancer survivors, founded and run by Priscilla Furth, MD, the study's co-author. The data included demographics, physical activity levels and cancer treatment type, duration and time since their treatment. Fitness assessments were conducted using a three-minute step test during a clinic visit. The purpose of the study was to access the step test as a way of determining a patient's current cardiovascular fitness level.

LeMoine says, "Often, what people think they are physically capable of doing and what they can actually do are two very different things. Many have a better fitness level than they expect while some find they're not as fit as they thought. The step-test gives us a better idea of their exercise tolerance and cardiovascular-fitness."

All the patients in the study were women and were diverse by age and body mass index. Their cancer diagnoses and treatments varied. Overall, 33 percent of the survivors were sedentary and 67 percent reported being physically active. Thirty-five (71 percent) of the participants completed the step test. Test completion and heart rate recovery were not affected by treatment, BMI, or age.

"What's really exciting to us was that we found that cardiovascular fitness was not affected by the expected culprits -- cancer treatment, type, duration or time since treatment," LeMoine explains. "That isn't to say there aren't side-effects of some treatments that may hinder physical activity, but when it comes to actual cardiovascular fitness as measured in our clinic, many of the standard treatments didn't have a role."

"We've modified an in-clinic cardiovascular assessment tool , the three-minute step test, with the goal of finding a test that can easily and quickly be performed in a physician's office," explains Priscilla A. Furth, MD, a professor of oncology and medicine at Lombardi. "Having this kind of evaluation tool is critical for physicians, like me, who are interested in prescribing physical activity for this population."


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Health and Advocacy Leaders Mobilize to Bring Attention to Atrial Fibrillation, a Costly and Misunderstood Cardiovascular Disease
2. Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events
3. The cardiovascular benefits of daily exercise in school children are evident even after 1 year
4. 30-year follow-up study: Tremendous impact of smoking on mortality and cardiovascular disease
5. More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure
6. The cardiovascular benefits of daily exercise in school children are evident even after one year
7. New Research Demonstrates that Wild Blueberries May Support Cardiovascular Health
8. MedAptus Charge Capture Technology Deployed at Leading Manhattan Cardiovascular Practice
9. SCAI Statement on A National Study of the Effect of Individual Proton Pump Inhibitors on Cardiovascular Outcomes in Patients Treated with Clopidogrel Following Coronary Stenting: The Clopidogrel Medco Outcomes Study
10. CorMatrix Cardiovascular to Present on its ECM Technology(TM) at the Annual Advanced Cardiac Techniques in Surgery (ACTS) Symposium in New York, N.Y.
11. VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
(Date:12/2/2016)... ... ... Mediaplanet is proud to announce the launch of its ... therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage their ... the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This is ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional ... Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to extend ... , The demand for supplemental training related to pain management has surged dramatically ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)...   Pairnomix, LLC, a genetic research company and ... the White House, today announced that findings from its first ... candidate therapies for a patient with epileptic encephalopathy caused by ... at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process involves ...
(Date:12/4/2016)... EAST HANOVER, N.J. , Dec. 3, 2016 /PRNewswire/ ... SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the ... by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) ... Novartis today announced that the data are being featured ... American Society of Hematology (ASH) Annual Meeting and ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: